Published in Clin Infect Dis on June 19, 2007
Extended Treatment With Vancomycin for Clostridium Difficile Colitis | NCT00861887
Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol (2009) 7.89
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10
Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol (2011) 3.81
Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol (2010) 2.61
Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis (2013) 2.22
The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun (2012) 2.02
Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol (2009) 1.97
Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother (2008) 1.87
Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev (2013) 1.85
Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol (2010) 1.82
The economic burden of Clostridium difficile. Clin Microbiol Infect (2011) 1.74
Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother (2008) 1.71
Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2012) 1.67
Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis (2012) 1.60
Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis (2012) 1.55
Clostridium difficile infection: guideline-based diagnosis and treatment. Dtsch Arztebl Int (2014) 1.47
Preoperative Clostridium difficile infection is not associated with an increased risk for the infection in ileal pouch patients. Dig Dis Sci (2014) 1.39
Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis (2012) 1.39
Mouse relapse model of Clostridium difficile infection. Infect Immun (2011) 1.36
The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis (2013) 1.36
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther (2010) 1.35
Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother (2011) 1.33
Clostridium difficile infection: a worldwide disease. Gut Liver (2014) 1.33
Clostridium difficile infection: new insights into management. Mayo Clin Proc (2012) 1.23
Gastrointestinal function in intensive care patients: terminology, definitions and management. Recommendations of the ESICM Working Group on Abdominal Problems. Intensive Care Med (2012) 1.22
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun (2012) 1.22
Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol (2012) 1.19
In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother (2012) 1.19
Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PLoS One (2012) 1.19
Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother (2013) 1.19
Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong. Eur J Clin Microbiol Infect Dis (2011) 1.18
Clostridium difficile infection. Am J Med Sci (2010) 1.17
Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Rev Gastroenterol Hepatol (2016) 1.13
Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci (2010) 1.13
Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. Gastroenterol Res Pract (2011) 1.11
Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant (2009) 1.10
Clostridium difficile outcomes difficult to generalize. Crit Care (2013) 1.09
Bench-to-bedside review: Clostridium difficile colitis. Crit Care (2008) 1.08
Emergence of Clostridium difficile ribotype 027 in Korea. Korean J Lab Med (2011) 1.08
Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis (2014) 1.08
Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant (2010) 1.08
Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol (2012) 1.07
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole. J Infect Dis (2015) 1.04
Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis (2010) 1.04
Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis (2012) 1.04
Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate. PLoS One (2013) 1.04
Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model. Antimicrob Agents Chemother (2012) 1.03
A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis (2014) 1.02
Current state of Clostridium difficile treatment options. Clin Infect Dis (2012) 1.02
Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis (2013) 1.02
Clostridium difficile in the ICU: the struggle continues. Chest (2011) 1.01
Recurrent Clostridium difficile infection: From colonization to cure. Anaerobe (2015) 1.00
The Bristol stool scale and its relationship to Clostridium difficile infection. J Clin Microbiol (2014) 1.00
Diarrhoea in the ICU: respective contribution of feeding and antibiotics. Crit Care (2013) 0.99
Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother (2012) 0.99
Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol (2010) 0.97
Reducing the risk of severe complications among patients with Clostridium difficile infection. Can J Gastroenterol (2011) 0.96
Impact of ribotype 027 on Clostridium difficile infection in a geriatric department. Eur J Clin Microbiol Infect Dis (2013) 0.94
Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother (2014) 0.94
Clostridium difficile outbreaks: prevention and treatment strategies. Risk Manag Healthc Policy (2012) 0.94
Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am (2009) 0.93
Vancomycin revisited - 60 years later. Front Public Health (2014) 0.93
The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge. Zoonoses Public Health (2010) 0.93
Risk Factors for Treatment Failure and Recurrence after Metronidazole Treatment for Clostridium difficile-associated Diarrhea. Gut Liver (2010) 0.92
Comparative in vitro activities of SMT19969, a new antimicrobial agent, against 162 strains from 35 less frequently recovered intestinal Clostridium species: implications for Clostridium difficile recurrence. Antimicrob Agents Chemother (2013) 0.91
A prospective study of risk factors and historical trends in metronidazole failure for Clostridium difficile infection. Clin Gastroenterol Hepatol (2008) 0.90
Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean tertiary hospital. J Korean Med Sci (2011) 0.89
Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review. Tech Coloproctol (2013) 0.89
Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol (2013) 0.89
Recognition and prevention of hospital-associated enteric infections in the intensive care unit. Crit Care Med (2010) 0.88
The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine (2010) 0.87
A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections. BMC Infect Dis (2015) 0.87
Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection. Eur J Clin Microbiol Infect Dis (2013) 0.87
Comparison of Illumigene, Simplexa, and AmpliVue Clostridium difficile molecular assays for diagnosis of C. difficile infection. J Clin Microbiol (2013) 0.87
Clostridium difficile Infection in Children: Current State and Unanswered Questions. J Pediatric Infect Dis Soc (2012) 0.86
Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol (2016) 0.86
Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. Antimicrob Agents Chemother (2012) 0.86
Probiotics in clostridium difficile Infection. J Clin Gastroenterol (2011) 0.86
Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother (2014) 0.86
Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother (2012) 0.86
Clostridium difficile--a moving target. F1000 Med Rep (2011) 0.85
Emergence of an outbreak-associated Clostridium difficile variant with increased virulence. J Clin Microbiol (2015) 0.85
Review of medical and surgical management of Clostridium difficile infection. Tech Coloproctol (2010) 0.85
Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027. Biol Blood Marrow Transplant (2014) 0.85
MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Chemother (2012) 0.85
WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg (2015) 0.85
Fidaxomicin therapy in critically ill patients with Clostridium difficile infection. Antimicrob Agents Chemother (2014) 0.84
Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. Dig Dis Sci (2014) 0.84
Clinical and microbiologic characteristics of tcdA-negative variant Clostridium difficile infections. BMC Infect Dis (2012) 0.84
Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance. Genes (Basel) (2015) 0.84
Immune-based treatment and prevention of Clostridium difficile infection. Hum Vaccin Immunother (2014) 0.84
The potential for emerging therapeutic options for Clostridium difficile infection. Gut Microbes (2014) 0.84
An agent-based simulation model for Clostridium difficile infection control. Med Decis Making (2014) 0.84
Synthetic polymers active against Clostridium difficile vegetative cell growth and spore outgrowth. J Am Chem Soc (2014) 0.84
Adherence to and Outcomes Associated with a Clostridium difficile Guideline at a Large Teaching Institution. Hosp Pharm (2015) 0.83
Clostridium difficile enteritis: A report of two cases and systematic literature review. World J Gastrointest Surg (2013) 0.83
Rational Therapy of Clostridium difficile Infections. Viszeralmedizin (2014) 0.83
Using oral vancomycin prescriptions as a proxy measure for Clostridium difficile infections: a spatial and time series analysis. Infect Control Hosp Epidemiol (2011) 0.83
Distal renal tubular acidosis and the potassium enigma. Semin Nephrol (2006) 1.15